Search - tctmd.com

Displaying 121 - 140 of 275

Sort: Relevancy | Date

News Opinion CV Team Dispatch

October 2020 News Roundup

L.A. McKeown

October 01, 2020

News Daily News

Even in Ideal Patients, Surgeons Aren’t Doing Multiarterial CABG

Shelley Wood

September 28, 2020

News Daily News

Hostility After ACS Linked to All-Cause Mortality

Michael O'Riordan

September 21, 2020

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

News Daily News

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

Yael L. Maxwell

September 14, 2020

News Conference News ESC 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

Caitlin E. Cox

September 03, 2020

News Daily News

Higher BP May Limit Myocardial Injury in AMICS

Caitlin E. Cox

August 10, 2020

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Daily News

Who Should Head to the Cath Lab in the COVID-19 Pandemic?

Michael O'Riordan

March 26, 2020

News Daily News

Meta-analysis Questions PCI vs CABG in Women With Multivessel Disease

Shelley Wood

February 27, 2020

News Daily News

PCI for Preventing Death in Unstable vs Stable CAD: New Data, More Soul-searching

Shelley Wood

February 19, 2020

News Daily News

Clopidogrel Interaction With Morphine in ACS Linked to More Ischemic Events

Shelley Wood

January 20, 2020

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Daily News

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Michael O'Riordan

December 03, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Opinion Off Script AHA 2019

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

Ajay Kirtane, MD, SM

November 12, 2019

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

Todd Neale

September 02, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Industry News

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

July 15, 2019

Advertisement

October 2020 News Roundup

Even in Ideal Patients, Surgeons Aren’t Doing Multiarterial CABG

Hostility After ACS Linked to All-Cause Mortality

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

Higher BP May Limit Myocardial Injury in AMICS

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Who Should Head to the Cath Lab in the COVID-19 Pandemic?

Meta-analysis Questions PCI vs CABG in Women With Multivessel Disease

PCI for Preventing Death in Unstable vs Stable CAD: New Data, More Soul-searching

Clopidogrel Interaction With Morphine in ACS Linked to More Ischemic Events

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content